Tekmira Pharmaceuticals Corporation Provides Periodic Update to Shareholders Regarding Litigation

Published: Jul 17, 2012

VANCOUVER, British Columbia, July 17, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a periodic update to its shareholders on the ongoing litigation with Alnylam Pharmaceuticals, Inc. and AlCana Technologies, Inc.

Back to news